Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 241.4% in Annexon, Inc. (ANNX). While the effectiveness of this highly sought-after metric is questionable, the...
The mean of analysts' price targets for Annexon, Inc. (ANNX) points to a 246.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...
Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts...
Proceeds Support Advancement of Broad Pipeline of Novel Complement Product Candidates for Diseases of the Body, Brain and Eye...
BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the...
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts...